Pharmaceutical Firms

The share price of Kwality Pharmaceuticals hit a new high of ₹3,130.85 on Monday. The stock zoomed 183% thus far in the calendar year 2026.

In the past six months, the stock price of Neuland Labs outperformed the market by surging 68 per cent, as compared to 6 per cent decline in the BSE Sensex.

Strong custom synthesis growth, peptide opportunities and higher earnings estimates support Divi's outlook, but elevated valuations could restrict further stock upside

Industry body says it is open to a shorter regulatory data protection period if the clock starts from a drug's marketing approval in India rather than its first global approval

Indian pharma companies are expanding selectively in the US for complex products while retaining India as their manufacturing base despite Trump's tariff threat

Ajanta Pharma Ltd on Thursday reported a 31 per cent rise in profit after tax to Rs 334 crore for the first quarter ended June 30. The company had posted a profit after tax (PAT) of Rs 255 crore in the corresponding period of the last fiscal, Ajanta Pharma said in a regulatory filing. Its revenue from operations grew 25 per cent to Rs 1,626 crore in the first quarter against Rs 1,303 crore in the year-ago period, it added. Branded generics revenue in India increased 24 per cent to Rs 509 crore from Rs 409 crore a year ago, the company said. US generic revenue jumped 57 per cent to Rs 487 crore compared to Rs 310 crore in the year-ago period, it noted.

Food regulator FSSAI has suspended the licence of Dior Pharmaceuticals for multiple violations at its nutraceutical factory. In a social media post on Thursday, FSSAI observed "serious non-compliances" during the inspection of the manufacturing unit in Punjab. "The Nutraceutical Manufacturing Unit was found to be operating under severely deficient Good Manufacturing Practices (GMP), Good Hygiene Practices (GHP), and Food Safety Management Systems (FSMS)," the Food Safety and Standards Authority of India (FSSAI) said. Stating that the deficiencies pose a significant risk to public health, FSSAI said there has been a gross non-compliance with the FSS Act, 2006. "The FSSAI Licence has been suspended with immediate effect. The FBO (food business operator) has been directed to immediately cease all operations until all deficiencies are rectified and compliance is established to the satisfaction of the Competent Authority," the regulator said. Giving details about major and critical ...

From generics to global leadership, India's pharmaceutical industry has transformed since 1991. Its next challenge is becoming a global hub for breakthrough drug innovation

India's pharmaceutical industry should treat the proposed US tariffs on imported generic medicines as a wake-up call to reduce dependence on a single export market, diversify globally and accelerate innovation while ensuring uninterrupted access to affordable medicines, industry leaders and healthcare experts said. US President Donald Trump has announced a phased tariff framework under which imported generic medicines will continue to attract zero tariffs until August 1, 2028, before facing a 100 per cent tariff for one year and a 200 per cent tariff from August 1, 2029. The proposal, aimed at encouraging drug manufacturing in the US, has triggered a debate within India's pharmaceutical sector over its long-term implications. Nikhil K Masurkar, CEO, ENTOD Pharmaceuticals, described the proposed tariffs as an opportunity for long-term strategic transformation, rather than merely a trade challenge. "The finer details of the proposed US tariffs on generic drugs are still unclear, but

Divi's Laboratories MD Murali K Divi topped India's pharma executive pay chart in FY26 with ₹100.26 crore, driven almost entirely by profit-linked commission

Improved market access and zero tariffs under the India-UK trade agreement are expected to lift Indian pharmaceutical exports to over $980 million in FY27

Drugmaker says it will supply 6-7 million pens in the last two quarters of FY27 and restart production by November after resolving the API-related quality issue

Industry says amendments reduce procedural burden while tightening documentation and record-keeping norms for drug manufacturers under the pricing order

Draft amendments propose a 12-month minimum residual shelf life for imported drugs and an acknowledgement-based mechanism for importing medicines for research

The joint venture will invest over $20 million in a pharmaceutical manufacturing facility in Sri Lanka to boost local drug production and reduce reliance on imports

The drug pricing regulator has directed manufacturers to regularly furnish production and sales data for scheduled formulations to strengthen monitoring of essential medicines

HRV Pharma owns drug master files and customer relationships while outsourcing production to 53 manufacturing partners, aiming to scale without owning factories

Brokerage says India should focus on specialty medicines and incremental innovation rather than copying Big Pharma's new-drug discovery model

Clears way for higher rates for Cisplatin and Carboplatin amid supply crunch

India plans a new support scheme for bulk drugs focused on R&D and capacity creation, while ruling out a broad medicine price hike despite rising input costs